Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
HAMILTON, BERMUDA, March 22, 2016 -- DHT Holdings, Inc. (NYSE:DHT) has filed its 2015 annual report on Form 20-F with the US Securities and Exchange Commission. The report and the audited financial statements are available on http://hugin.info/150897/R/1996693/735844.pdf
Shareholders may request a hard copy of the audited financial statements free of charge by sending an e-mail to [email protected].
CONTACT: DHT Holdings, Inc.
Eirik Uboe, CFO
E-mail: [email protected] and [email protected]
Phone +1 441 299 4912
HUG#1996709
